Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,939 Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care
Type 2 Diabetes Mellitus · Prediabetic State
Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…
N/A N=23 Continuous Glucose Monitoring in Prediabetes
Pre-diabetes
Primary: Change in Mean Glucose (mg/dL) From Baseline — 2.1 mg/dL — p=0.8
Phase 4 N=24 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005
N/A N=95 Early Screening and Treatment of Women With Prediabetes in Pregnancy
Diabetes · Pregnancy
Primary: Number of Patients With a Diagnosis of Gestational Diabetes at 26 Weeks Gestation. — 19; 23 Participants — p=0.32
N/A N=21,664 Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)
Pre-diabetes
Primary: Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke — 1.100; 1.096 units on a scale — p=<0.05
N/A N=115 Precision Diets for Diabetes Prevention
Pre Diabetes · Insulin Resistance · Diabetes Mellitus, Type 2
Primary: Change in Glycemic Control as Measured by Change Blood Sugar Values — 88.9; 95.4; 90.8; 96.7 mg/dL — p=<0.001
Phase 4 N=22 Incretins in Impaired Fasting Glucose
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05
Phase 4 N=20 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
Prediabetes · Obesity
Primary: Monocyte NfkB Levels as Detected by Western Blotting — 62.79; 72.03; 67.68; 84.19 NfkB p65 arbitrary units
Phase 2 N=60 BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes
Pre-Diabetes
Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57
N/A N=15 Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes
Pre-diabetes
Primary: Participant Satisfaction With Continuous Glucose Monitoring (CGM) — 10; 4; 1; 0 participants
N/A N=35 CGM Plus GEM in Prediabetes
PreDiabetes
Primary: Change in Percentage of CGM Glucose Readings > 120 mg/dL — 25.0; 21.5; 16.9; 21.7 percentage of CGM readings
N/A N=88 Beta Cell Restoration Through Fat Mitigation
Prediabetes · Type 2 Diabetes · Obesity
Primary: Steady State Beta Cell Compensation — 3.01; 3.19 (nmol/L) adjusted for M/I — p=0.05
N/A N=6,588 Comparison of Outreach Methods to Encourage Enrollment in Diabetes Prevention and Weight Management Programs
PreDiabetes · Obesity
Primary: Enrollment in Diabetes Prevention or Weight Management Class (Online) — 7; 12; 39; 59 Participants — p=<0.001
N/A N=24 Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion
Glucose Intolerance
Primary: Postprandial Glucose Levels at Week 12 — 9.5; 9.9 mmol/L — p=0.380
N/A N=39 Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Prediabetic State
Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose…
N/A N=23 Continuous Glucose Monitoring in Diabetes and Prediabetes
Diabetes Mellitus, Type 2 · PreDiabetes · Obesity
Primary: Percent Change in BMI From Baseline to 14 Weeks — -0.3; -0.2 % change over 14 weeks
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=62 Evaluating a Type 2 Diabetes Prevention Program
Type 2 Diabetes · PreDiabetes
Primary: Body Mass Index (BMI) - Post-Test — 30.3; 28.8 kg/m2
N/A N=122 Interdisciplinary and Family Intervention to Prevent Type 2 Diabetes
Prediabetes
Primary: Individual Insulin Resistance and Insulin Secretion — 4.9; 4.8 score on a scale — p=0.844
N/A N=187 Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation
Type 2 Diabetes Mellitus · Colonoscopy
Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants
Phase 3 N=21 Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
Impaired Fasting Glucose · Prediabetes
Primary: Acute Insulin Response (AIRg) to Intravenous Glucose — 1866; 1752 pmol/1*min
N/A N=117 Vitamin D in Minorities With Prediabetes
Pre-diabetes
Primary: Percent of Subjects Who Develop Diabetes — 9; 12 percentage of participants — p=0.61
Phase 3 N=302 Enhancing Fitness in Older Pre-diabetic Veterans
Impaired Glucose Tolerance · Obesity · Diabetes
Primary: Fasting Insulin — 10.26; 10.39 uIU/ml
Phase 4 N=30 Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension
PreDiabetes · Prehypertension
Primary: 24-hours Systolic Blood Pressure at Week 12 — 117; 120 mmHg — p=0.755
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=130 Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform
PreDiabetes · Glucose Metabolism Disorders · Diabetes Mellitus
Primary: Number of Participants With Insulin Resistance — 69 Participants
Phase 2 N=18 Walnuts to Achieve Lasting NUTrition to Prevent Diabetes
PreDiabetes · Overweight and Obesity
Primary: Number of Participants Recruited and Retained — 8; 9 Participants
N/A N=51 The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers
Prediabetes
Primary: GLP-1 Levels in Response to Oral Glucose Tolerance Test — 16.66; 18.57 pmol/l.h — p=0.209
Phase 3 N=602 Actos Now for Prevention of Diabetes (ACT NOW)
Impaired Glucose Tolerance · Type 2 Diabetes
Primary: Prevention of Type 2 Diabetes — 16.1; 5.0 percentage of participants